{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:35:20Z","timestamp":1793432120498,"version":"4.5.0"},"reference-count":78,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.1001\/jamaoncol.2021.0580","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T16:26:59Z","timestamp":1620404819000},"page":"1231","source":"Crossref","is-referenced-by-count":104,"title":["Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Ruby M.","family":"van Stein","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend G. J.","family":"Aalbers","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[{"name":"Center for Gynecologic Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"crv210002r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/07357907.2012.654871","article-title":"Peritoneal carcinomatosis: cytoreductive surgery and HIPEC\u2014overview and basics.","volume":"30","author":"Br\u00fccher","year":"2012","journal-title":"Cancer Invest"},{"issue":"2","key":"crv210002r2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"crv210002r3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","article-title":"Peritonectomy procedures.","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"crv210002r4","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy.","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"issue":"1","key":"crv210002r5","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"crv210002r6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum.","volume":"49","author":"van Baal","year":"2017","journal-title":"Tissue Cell"},{"issue":"3, pt 2","key":"crv210002r7","first-page":"F413","article-title":"A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat.","volume":"248","author":"Flessner","year":"1985","journal-title":"Am J Physiol"},{"issue":"7","key":"crv210002r8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.","volume":"89","author":"Dedrick","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"crv210002r9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000136874","article-title":"Transport of model compounds across the peritoneal membrane in the rat.","volume":"17","author":"Torres","year":"1978","journal-title":"Pharmacology"},{"issue":"1","key":"crv210002r10","first-page":"29","article-title":"Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.","volume":"7","author":"Sugarbaker","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"crv210002r11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/bjs5.v4.2","article-title":"Effect of intraperitoneal chemotherapy concentration on morbidity and survival.","volume":"4","author":"Elekonawo","year":"2020","journal-title":"BJS Open"},{"issue":"3","key":"crv210002r12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00228-012-1405-4","article-title":"Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.","volume":"69","author":"Cashin","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"crv210002r13","first-page":"311","article-title":"Kinetic and physical studies of cell death induced by chemotherapeutic agents or hyperthermia.","volume":"19","author":"Dyson","year":"1986","journal-title":"Cell Tissue Kinet"},{"issue":"1","key":"crv210002r14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1040-8428(01)00179-2","article-title":"The cellular and molecular basis of hyperthermia.","volume":"43","author":"Hildebrandt","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"crv210002r15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0301-472X(99)00104-6","article-title":"Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells.","volume":"27","author":"Multhoff","year":"1999","journal-title":"Exp Hematol"},{"issue":"5","key":"crv210002r16","first-page":"1252","article-title":"A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.","volume":"52","author":"Los","year":"1992","journal-title":"Cancer Res"},{"issue":"1","key":"crv210002r17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","article-title":"Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.","volume":"34","author":"van de Vaart","year":"1998","journal-title":"Eur J Cancer"},{"issue":"1","key":"crv210002r18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13014-015-0462-0","article-title":"Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all.","volume":"10","author":"Oei","year":"2015","journal-title":"Radiat Oncol"},{"issue":"24","key":"crv210002r19","doi-asserted-by":"publisher","first-page":"9851","DOI":"10.1073\/pnas.1101053108","article-title":"Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.","volume":"108","author":"Krawczyk","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"crv210002r20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejso.2015.08.162","article-title":"Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed.","volume":"42","author":"Kuijpers","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"crv210002r21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.suronc.2016.06.001","article-title":"Operating personnel safety during the administration of hyperthermic intraperitoneal chemotherapy (HIPEC).","volume":"25","author":"Kyriazanos","year":"2016","journal-title":"Surg Oncol"},{"issue":"1","key":"crv210002r22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010078","article-title":"Variation in clinical application of hyperthermic intraperitoneal chemotherapy: a review.","volume":"11","author":"Helderman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"crv210002r23","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/981245","article-title":"Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin.","volume":"2012","author":"Esquivel","year":"2012","journal-title":"Gastroenterol Res Pract"},{"issue":"10","key":"crv210002r24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"crv210002r25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"crv210002r26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands.","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer"},{"issue":"11","key":"crv210002r27","first-page":"937","article-title":"Diagnosis and management of ovarian cancer.","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am Fam Physician"},{"issue":"10","key":"crv210002r28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"28","key":"crv210002r29","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline.","volume":"34","author":"Wright","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"crv210002r30","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"crv210002r31","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer.","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"crv210002r32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer.","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"26","key":"crv210002r33","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer.","volume":"33","author":"Wright","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"crv210002r34","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study.","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv210002r35","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"crv210002r36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study.","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"16","key":"crv210002r37","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study.","volume":"37","author":"Walker","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv210002r38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer.","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"crv210002r39","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer.","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv210002r40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int J Cancer"},{"issue":"6","key":"crv210002r41","doi-asserted-by":"publisher","first-page":"845","DOI":"10.7326\/0003-4819-97-6-845","article-title":"Intraperitoneal cisplatin with systemic thiosulfate protection.","volume":"97","author":"Howell","year":"1982","journal-title":"Ann Intern Med"},{"issue":"1","key":"crv210002r42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.","volume":"47","author":"Koole","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"crv210002r43","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e53","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.","volume":"29","author":"Ceresoli","year":"2018","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"crv210002r44","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"15 suppl","key":"crv210002r45","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20.","volume":"38","author":"Bois","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv210002r46","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"crv210002r47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/IGC.0000000000000864","article-title":"Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al.","volume":"27","author":"Harter","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"crv210002r49","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1136\/ijgc-2020-001825","article-title":"Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"crv210002r50","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1002\/cncr.v125.s24","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on.","volume":"125","author":"Koole","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"crv210002r51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: ovarian cancer, version 1.2019: featured updates to the NCCN guidelines.","volume":"17","author":"Armstrong","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"crv210002r52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3747\/co.27.6033","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.","volume":"27","author":"Auer","year":"2020","journal-title":"Curr Oncol"},{"issue":"6","key":"crv210002r53","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1245\/s10434-020-08322-y","article-title":"The Chicago Consensus on Peritoneal Surface Malignancies: management of ovarian neoplasms.","volume":"27","author":"Hoppenot","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"crv210002r54","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.","author":"Colombo","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"crv210002r55","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1200\/JCO.19.00594","article-title":"Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial.","volume":"37","author":"Koole","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv210002r56","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.","volume":"99","author":"Segelman","year":"2012","journal-title":"Br J Surg"},{"issue":"12","key":"crv210002r57","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"crv210002r58","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.clcc.2015.12.006","article-title":"Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study.","volume":"15","author":"Razenberg","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"13","key":"crv210002r59","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1245\/s10434-014-3798-z","article-title":"The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis.","volume":"21","author":"Esquivel","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"crv210002r60","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"crv210002r61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015: a systematic review.","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"crv210002r62","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (ProphyloCHIP-PRODIGE 15): a randomised, phase 3 study.","volume":"21","author":"Go\u00e9r\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"crv210002r65","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/codi.13593","article-title":"Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.","volume":"19","author":"Klaver","year":"2017","journal-title":"Colorectal Dis"},{"issue":"12","key":"crv210002r66","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.ejso.2018.07.003","article-title":"The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).","volume":"44","author":"Bushati","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"crv210002r67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"crv210002r68","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","article-title":"Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).","volume":"19","author":"Rovers","year":"2019","journal-title":"BMC Cancer"},{"key":"crv210002r69","article-title":"Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.","author":"Nagourney","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"crv210002r70","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.","volume":"109","author":"Hompes","year":"2014","journal-title":"J Surg Oncol"},{"issue":"2","key":"crv210002r71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","article-title":"Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.","volume":"44","author":"van Eden","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"crv210002r72","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.v110.7","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J Surg Oncol"},{"issue":"1","key":"crv210002r73","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","article-title":"Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.","volume":"43","author":"Leung","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"10, pt A","key":"crv210002r74","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","article-title":"Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study.","volume":"46","author":"Bakkers","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"crv210002r75","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","article-title":"Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.","volume":"106","author":"Ubink","year":"2019","journal-title":"Br J Surg"},{"issue":"9","key":"crv210002r76","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.","volume":"22","author":"Go\u00e9r\u00e9","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"crv210002r77","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/SLA.0000000000001593","article-title":"Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis.","volume":"263","author":"Kwakman","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"crv210002r78","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1002\/bjs.10788","article-title":"Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.","volume":"105","author":"Ubink","year":"2018","journal-title":"Br J Surg"},{"key":"crv210002r48","unstructured":"ClinicalTrials.gov. Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment (CHIPOR). NCT01376752. Accessed February 1, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01376752"},{"key":"crv210002r63","unstructured":"ClinicalTrials.gov. Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma (HIPECT4). NCT02614534. Accessed February 1, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02614534"},{"key":"crv210002r64","unstructured":"ClinicalTrials.gov. Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases (COLOPEC-II). NCT03413254. Accessed February 1, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03413254"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2779523\/jamaoncology_van_stein_2021_rv_210002_1628879140.0467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:31:16Z","timestamp":1698996676000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2779523"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.0580","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}